ACADIA Pharmaceuticals Inc Insider Trading
Every director, officer and 10% holder of ACADIA Pharmaceuticals Inc has to report each trade in its stock within two business days of making it. This is those filings.
ACAD on carbonthat →Purchases and sales
Open-market trades only — the lines where someone chose to buy or sell at the going price.
| Insider | Action | Value |
|---|---|---|
| Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-065K shat $29.00 | Sale10b5-1 plan | $145K |
| Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-069.3K shat $29.34 | Sale10b5-1 plan | $272.6K |
| Mark C. SchneyerEVP, CHIEF FINANCIAL OFFICER2026-08-055.8K shat $29.00 | Sale10b5-1 plan | $169.6K |
| Elizabeth H.Z. ThompsonEVP, Head of Research & Dev2026-07-3016.5K shat $26.13 | Sale | $431.4K |
| Elizabeth H.Z. ThompsonEVP, Head of Research & Dev2026-07-3050 shat $26.17 | Sale | $1.3K |
| James KiharaPRINCIPAL ACCOUNTING OFFICER2026-06-2611.4K shat $26.08 | Sale10b5-1 plan | $297.9K |
Source: SEC Form 4 filings, via EDGAR. A derivative line reports the shares underlying an option rather than stock outstanding, so it is marked and is not comparable with the rest. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
More on ACAD
Follow ACADIA Pharmaceuticals Inc (ACAD) by email
New trades in ACADIA Pharmaceuticals Inc (ACAD) by members of Congress, insiders and funds, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.